Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02762006 · ClinicalTrials.gov registry record · Phase 1
Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
A Phase 1 study of Renal Cell Carcinoma and Kidney Cancer, sponsored by Moshe Ornstein.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
- 2
- Study locations
NCT02762006 is a Phase 1 study of Renal Cell Carcinoma and Kidney Cancer that has completed, run by Moshe Ornstein. The registered enrollment target is 29 participants, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (88% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT02762006, a Phase 1 study of Renal Cell Carcinoma and Kidney Cancer, has completed, sponsored by Moshe Ornstein.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to investigate the safety and feasibility of administering investigational drugs (meaning not Food and Drug Administration (FDA)-approved for kidney cancer) prior to surgical treatment for kidney cancer. The first drug is called MEDI4736, and the second drug is called tremelimumab. Both of these drugs work by attaching to certain proteins on immune cells with the goal of stimulating an immune response against cancer cells. This is a phase 1 trial, with the primary goal of identifying if this treatment is safe and possible side effects when given prior to surgery for kidney cancer.
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG Tremelimumab
Study Locations (2)
Minnesota
- University of Minnesota - Minneapolis
Ohio
- Cleveland Clinic, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2016-12-20 |
| Est. Completion | 2020-11-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02762006
The ClinicalTrials.gov registry entry for NCT02762006 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 243-participant average among 121 other Renal Cell Carcinoma trials with a reported enrollment target (88% lower). The listed sponsor is Moshe Ornstein, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Renal Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT02762006 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Minnesota, Ohio.
Frequently Asked Questions
What is clinical trial NCT02762006 about?
NCT02762006 is a clinical study titled "Neoadjuvant MEDI 4736 +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma". The purpose of this study is to investigate the safety and feasibility of administering investigational drugs (meaning not Food and Drug Administration (FDA)-approved for kidney cancer) prior to surgical treatment for kidney cancer. The first drug is called MEDI4736, and the second drug is called tr...
What is the current status of trial NCT02762006?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2016-12-20. Estimated completion is 2020-11-06.
What conditions does trial NCT02762006 study?
This clinical trial studies the following conditions: Renal Cell Carcinoma, Kidney Cancer.
What interventions are being tested in trial NCT02762006?
The interventions under investigation include: Durvalumab (DRUG), Tremelimumab (DRUG).
Who is sponsoring clinical trial NCT02762006?
This trial is sponsored by Moshe Ornstein, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02762006 being conducted?
This trial has 2 study locations across Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Renal Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma
RECRUITING · Phase 1
-
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RECRUITING · Phase 1
-
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
-
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.